Mycio Wealth Partners LLC held its stake in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,842 shares of the biopharmaceutical company’s stock at the end of the second quarter. Celgene Corporation makes up approximately 0.6% of Mycio Wealth Partners LLC’s portfolio, making the stock its 21st biggest holding. Mycio Wealth Partners LLC’s holdings in Celgene Corporation were worth $5,206,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter valued at approximately $118,000. Acropolis Investment Management LLC acquired a new position in Celgene Corporation during the second quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Rational Advisors LLC acquired a new position in Celgene Corporation during the second quarter valued at approximately $156,000. Finally, Oakworth Capital Inc. lifted its position in Celgene Corporation by 11.7% during the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 127 shares in the last quarter. 79.39% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have weighed in on CELG. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a research report on Thursday, August 10th. UBS AG cut shares of Celgene Corporation from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price on the stock. in a research report on Thursday, October 26th. BMO Capital Markets reduced their target price on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. SunTrust Banks, Inc. set a $150.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. Finally, Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $139.64.
ILLEGAL ACTIVITY NOTICE: “Mycio Wealth Partners LLC Continues to Hold Stake in Celgene Corporation (CELG)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/11/01/mycio-wealth-partners-llc-continues-to-hold-stake-in-celgene-corporation-celg.html.
In other news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,733 shares of company stock valued at $5,259,359. 0.95% of the stock is currently owned by corporate insiders.
Shares of Celgene Corporation (CELG) opened at 100.97 on Wednesday. The company has a 50-day moving average of $134.67 and a 200 day moving average of $129.65. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The firm has a market cap of $78.99 billion, a P/E ratio of 31.27 and a beta of 1.88.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company posted $1.58 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Equities analysts predict that Celgene Corporation will post $7.33 EPS for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.